Pharma BD Deal Intelligence

Tolerance Bio, Inc. / Tanabe Pharma Corporation

2026 · Licensing/Option · $560M · Complete

Tolerance Bio licensed MT-2990, now TLB-33, a clinical-stage fully human anti-IL-33 monoclonal antibody, from Tanabe Pharma. The exclusive agreement grants Tolerance Bio worldwide development rights and exclusive commercialisation rights outside Japan; Tanabe Pharma retains Japanese commercialisation rights. Consideration comprises equity, tiered royalties on net sales and development and sales milestones of up to USD 560 million; no upfront cash payment was disclosed. Tolerance Bio plans to begin Phase 2 development of TLB-33 in 2027 to assess whether IL-33 blockade preserves thymic function during inflammation, extending its thymus-focused pipeline strategy.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals